

Author Response

In response to reviewers of:

Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries

Responding reviewer 1:

A) We have increased (over 3 paragraphs) our discussion of precision oncology in developing countries. In the added text, we discuss the benefits of clinical trials and compassionate use of drugs in the resource-limited setting. Added text is highlighted in the new submission.

B) To our current knowledge there is no established workflow for screening against NTRK rearrangements. Therefore, we consider that these mutations should be sought only in tumors where a relatively high frequency of NTRK mutations have been reported. We added this recommendation to the text. Added text is highlighted in the new submission.

Responding reviewer 2:

C) We added a paragraph discussing the use of compassionate use of drugs as an option of treatment access in developing countries. Added text is highlighted in the new submission.

D) We added a note stating that clinical trials in developing countries should be conducted in accordance to the highest quality standards. Added text is highlighted in the new submission.